Posted inSectors

Lupin launches authorised generic version of Antara in the United States

Fenofibrate Capsules (RLD: Antara Capsules) had estimated annual sales of USD 7 million in the U.S.

by Ameen Syed
Lupin launches authorised generic version of Antara in the United States

 Global pharma major Lupin Limited (Lupin) announced the launch of the authorised generic version of Antara (Fenofibrate) Capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, S.A. Corporation, a wholly-owned subsidiary of Lupin. 

Fenofibrate Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia. 

Fenofibrate Capsules (RLD: Antara Capsules) had estimated annual sales of USD 7 million in the U.S.  (IQVIA MAT September 2021).